$0.60 is intrinsic valuation on forward cashflows based on moderate assumptions. Like the amount of beds they can have contracted by 2024. The pricing staying same (which I don't think but assuming if it still would be $5 per bed /month).
Ofcourse the market could pay a 20x premium on the valuation. Also, the company can grow much faster than the base case assumption. Unfortunately we are not living 2023, so we are just guesstimating. Bottom line is base case is pre good aswell for PCK.
Ann: DACS Grant Funding Contract for National Trial Signed, page-68
-
- There are more pages in this discussion • 81 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PCK (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.8¢ |
Change
-0.002(6.67%) |
Mkt cap ! $45.84M | |||
| Open | High | Low | Value | Volume |
| 2.9¢ | 2.9¢ | 2.8¢ | $7.462K | 257.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1209083 | 2.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.9¢ | 60000 | 1 |
View Market Depth
| Last trade - 14.48pm 18/11/2024 (20 minute delay) ? |
| PCK (ASX) Chart |